Originally published by our sister publication Clinical Oncology News
By Ted Bosworth
In patients with unresectable epidermal growth factor receptor−mutated (EGFRm), stage III non-small cell lung cancer (NSCLC), osimertinib (Tagrisso, Astra Zeneca) appears destined to become the new standard consolidation therapy after chemoradiotherapy. There is no currently approved consolidation therapy for these patients.
With the “robust magnitude of benefit,” osimertinib “provides a